Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10873788rdf:typepubmed:Citationlld:pubmed
pubmed-article:10873788lifeskim:mentionsumls-concept:C0012655lld:lifeskim
pubmed-article:10873788lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:10873788lifeskim:mentionsumls-concept:C0039194lld:lifeskim
pubmed-article:10873788lifeskim:mentionsumls-concept:C0079864lld:lifeskim
pubmed-article:10873788lifeskim:mentionsumls-concept:C0040711lld:lifeskim
pubmed-article:10873788lifeskim:mentionsumls-concept:C0003316lld:lifeskim
pubmed-article:10873788lifeskim:mentionsumls-concept:C0034754lld:lifeskim
pubmed-article:10873788lifeskim:mentionsumls-concept:C0205369lld:lifeskim
pubmed-article:10873788lifeskim:mentionsumls-concept:C0683598lld:lifeskim
pubmed-article:10873788lifeskim:mentionsumls-concept:C1523987lld:lifeskim
pubmed-article:10873788pubmed:issue2lld:pubmed
pubmed-article:10873788pubmed:dateCreated2000-8-15lld:pubmed
pubmed-article:10873788pubmed:abstractTextMurine AIDS (MAIDS) develops in susceptible mouse strains after infection with the LP-BM5 murine leukemia virus complex that contains causative defective, and ecotropic helper, retroviruses. We previously demonstrated that the MAIDS-resistant H-2(d) strains BALB/cByJ and C57BL/KsJ generate MHC class I (K(d)) restricted virus-specific CD8(+) cytolytic T lymphocytes (CTLs) that lyse cells expressing either defective or ecotropic gag proteins. In contrast, the congenic BALB.B and closely related C57BL/6J MAIDS-susceptible H-2(b) strains were unable to serve as a source of gag-specific CTLs (Schwarz and Green, 1994), suggesting that anti-gag CTLs might provide a basis for resistance to MAIDS. Although its susceptibility to MAIDS was unknown, the (BALB/c x C57BL/6J) F(1) (CBY6F(1)) strain could also produce H-2(d)-, but not H-2(b)-, restricted, anti-gag CTLs (Schwarz and Green, 1994). Because of this correlation between anti-gag CTLs and resistance to MAIDS, it was important to provide more direct evidence in support of CTL-mediated protection and to determine both the fine specificity of CByB6F(1) anti-gag CTLs, in comparison with the resistant C57BL/Ks and BALB/c strains, and the susceptibility of this F(1) strain to LP-BM5-induced MAIDS. We report here that no symptoms of MAIDS were observed in CBY6F(1) (H-2(dxb)) mice. For F(2) mice, in contrast to the high susceptibility of H-2(b/b) mice, 77% of H-2(d/d) and 81% of H-2(b/d) F(2) mice did not exhibit MAIDS after LP-BM5 infection. These results are in contrast to other published studies that concluded that susceptibility, rather than resistance, is dominant in F(1) (resistant x susceptible or susceptible x resistant) mice. We also show that CBY6F(1) anti-gag CTLs exhibit a fine specificity shared by the MAIDS-resistant BALB/c and C57BL/Ks strains, that is, the immunodominant gag epitope, SYNTGRFPPL, encoded by an alternative open reading frame. Together with our direct demonstration here that in vivo monoclonal antibody (mAb) depletion of CD8(+) T cells converts genetically resistant mice to MAIDS susceptibility, these data on the ability to mount anti-ORF2/SYNTGRFPPL, gag-specific CTL responses strongly suggest that CTLs are a primary factor in determining MAIDS resistance. Accordingly, given the K(d)-restricted nature of the CTLs, the main genetic determinant of resistance appeared to be the codominant expression of the resistant H-2(d) haplotype. Interestingly, however, 19% of H-2(d/b) and 23% of the H-2(d/d) F(2) mice had at least one clinical aspect of MAIDS, suggesting that a non-MHC genetic determinant(s) can negatively influence T-cell protection and thus disease outcomelld:pubmed
pubmed-article:10873788pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10873788pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10873788pubmed:languageenglld:pubmed
pubmed-article:10873788pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10873788pubmed:citationSubsetIMlld:pubmed
pubmed-article:10873788pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10873788pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10873788pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10873788pubmed:statusMEDLINElld:pubmed
pubmed-article:10873788pubmed:monthJullld:pubmed
pubmed-article:10873788pubmed:issn0042-6822lld:pubmed
pubmed-article:10873788pubmed:authorpubmed-author:GreenW RWRlld:pubmed
pubmed-article:10873788pubmed:authorpubmed-author:TorbettB EBElld:pubmed
pubmed-article:10873788pubmed:authorpubmed-author:HealyP APAlld:pubmed
pubmed-article:10873788pubmed:authorpubmed-author:MayrandS MSMlld:pubmed
pubmed-article:10873788pubmed:copyrightInfoCopyright 2000 Academic Press.lld:pubmed
pubmed-article:10873788pubmed:issnTypePrintlld:pubmed
pubmed-article:10873788pubmed:day5lld:pubmed
pubmed-article:10873788pubmed:volume272lld:pubmed
pubmed-article:10873788pubmed:ownerNLMlld:pubmed
pubmed-article:10873788pubmed:authorsCompleteYlld:pubmed
pubmed-article:10873788pubmed:pagination438-49lld:pubmed
pubmed-article:10873788pubmed:dateRevised2009-12-16lld:pubmed
pubmed-article:10873788pubmed:meshHeadingpubmed-meshheading:10873788...lld:pubmed
pubmed-article:10873788pubmed:meshHeadingpubmed-meshheading:10873788...lld:pubmed
pubmed-article:10873788pubmed:meshHeadingpubmed-meshheading:10873788...lld:pubmed
pubmed-article:10873788pubmed:meshHeadingpubmed-meshheading:10873788...lld:pubmed
pubmed-article:10873788pubmed:meshHeadingpubmed-meshheading:10873788...lld:pubmed
pubmed-article:10873788pubmed:meshHeadingpubmed-meshheading:10873788...lld:pubmed
pubmed-article:10873788pubmed:meshHeadingpubmed-meshheading:10873788...lld:pubmed
pubmed-article:10873788pubmed:meshHeadingpubmed-meshheading:10873788...lld:pubmed
pubmed-article:10873788pubmed:meshHeadingpubmed-meshheading:10873788...lld:pubmed
pubmed-article:10873788pubmed:meshHeadingpubmed-meshheading:10873788...lld:pubmed
pubmed-article:10873788pubmed:meshHeadingpubmed-meshheading:10873788...lld:pubmed
pubmed-article:10873788pubmed:meshHeadingpubmed-meshheading:10873788...lld:pubmed
pubmed-article:10873788pubmed:meshHeadingpubmed-meshheading:10873788...lld:pubmed
pubmed-article:10873788pubmed:meshHeadingpubmed-meshheading:10873788...lld:pubmed
pubmed-article:10873788pubmed:meshHeadingpubmed-meshheading:10873788...lld:pubmed
pubmed-article:10873788pubmed:meshHeadingpubmed-meshheading:10873788...lld:pubmed
pubmed-article:10873788pubmed:meshHeadingpubmed-meshheading:10873788...lld:pubmed
pubmed-article:10873788pubmed:meshHeadingpubmed-meshheading:10873788...lld:pubmed
pubmed-article:10873788pubmed:meshHeadingpubmed-meshheading:10873788...lld:pubmed
pubmed-article:10873788pubmed:year2000lld:pubmed
pubmed-article:10873788pubmed:articleTitleAnti-Gag cytolytic T lymphocytes specific for an alternative translational reading frame-derived epitope and resistance versus susceptibility to retrovirus-induced murine AIDS in F(1) mice.lld:pubmed
pubmed-article:10873788pubmed:affiliationDepartment of Microbiology, Dartmouth Medical School, One Medical Center Drive, Lebanon, New Hampshire, 03756, USA.lld:pubmed
pubmed-article:10873788pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10873788pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:10873788pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:10873788pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10873788lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10873788lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10873788lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10873788lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10873788lld:pubmed